TVB-2640
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
Conditions
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
Trial Timeline
Aug 12, 2021 → Oct 2, 2023
NCT ID
NCT04906421About TVB-2640
TVB-2640 is a phase 2 stage product being developed by Sagimet Biosciences for Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04906421. Target conditions include Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04906421 | Phase 2 | Completed |
| NCT03808558 | Phase 2 | Active |
| NCT02223247 | Phase 1 | Completed |
Competing Products
20 competing products in Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease